日韩女优狠狠,久久蜜芽天堂

Gilead's 2024 Financial Report Financial statements Gilead's 2024 revenue reached $28.75B, up 6%. Biktarvy led with $13.4B in sales, while CAR-T therapies generated $1.97B. HIV, oncology, and liver disease segments saw strong growth. Veklury sales declined. 2025 product sales forecast: $28.2B-$28.6B.
Gilead's Q3 Performance: Pipeline Cuts and CAR-T Sales Success Financial statements Gilead released Q3 Performance: Revenue for the first three quarters of 2024 was US$21.185 billion, a year-on-year increase of 6%; total revenue for Q3 2024 was US$7.545 billion, a year-on-year increase of 5%, mainly due to sales growth of the AIDS drug Veklury and oncology and liver disease drugs.
Gilead: Trial Failure, Withdraws Approval of Trodelvy for Bladder Cancer Treatment Gilead Gilead has voluntarily withdrawn Trodelvy's accelerated approval for bladder cancer after a failed confirmatory trial. While the drug's effectiveness in other cancers remains unaffected, the failure casts a shadow on its future, as competitors advance in the TROP2 ADC market.

< Pre 12Next>

Articles Archives

Hot Articles

All Categories

国产91视频久久,亚洲综合色图在线观看,五月天操逼网,日韩色色AV,青青在线A片,亚洲最大色在线观看,欧美熟妇丝袜诱惑,青青操逼视频,日韩无码操出水